Lormalzi Alzheimer Drug India
-
{
- All
- News
-
Who Should Take Lormalzi? Alzheimer's Expert Explains Benefits And Risks
Neurologists say Lormalzi (donanemab), India's newly launched Alzheimer's therapy, may help slow cognitive decline in carefully selected patients with early disease. Experts explain who may benefit, who should avoid it, and the risks involved.
-
Eli Lilly Launches Alzheimer's Drug Lormalzi Priced At Rs 91,688 Per Vial In India
Eli Lilly has launched Lormalzi (donanemab) in India for early Alzheimer's disease at Rs91,688 per vial. The once-monthly therapy targets amyloid plaques and may help slow cognitive decline in eligible patients with mild symptoms.
-
Who Should Take Lormalzi? Alzheimer's Expert Explains Benefits And Risks
Neurologists say Lormalzi (donanemab), India's newly launched Alzheimer's therapy, may help slow cognitive decline in carefully selected patients with early disease. Experts explain who may benefit, who should avoid it, and the risks involved.
-
Eli Lilly Launches Alzheimer's Drug Lormalzi Priced At Rs 91,688 Per Vial In India
Eli Lilly has launched Lormalzi (donanemab) in India for early Alzheimer's disease at Rs91,688 per vial. The once-monthly therapy targets amyloid plaques and may help slow cognitive decline in eligible patients with mild symptoms.
